Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
IDEAL
Atorvastatin Compared With Simvastatin In The Prevention of CHD Morbidity And Mortality In Patients With CHD
2 other identifiers
interventional
8,600
6 countries
193
Brief Summary
To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4 cardiovascular-diseases
Started Feb 1999
Longer than P75 for phase_4 cardiovascular-diseases
193 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 1999
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 8, 2005
CompletedFirst Posted
Study publicly available on registry
September 12, 2005
CompletedApril 22, 2015
April 1, 2015
September 8, 2005
April 21, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest
Secondary Outcomes (1)
1) Time to any CHD event, 2) Time to Hospitalization with primary diagnosis of CHF, 3) Time to Cerbrovascular Event, 4) Time to PAD, 5) Time to any CV event and 6) All Cause Mortality
Interventions
Eligibility Criteria
You may qualify if:
- Previous myocardial infarction
You may not qualify if:
- Women who are breast feeding or are pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (194)
Pfizer Investigational Site
Arhus C, DK-8000, Denmark
Pfizer Investigational Site
Copenhagen, 2100, Denmark
Pfizer Investigational Site
Elsinore, 3000, Denmark
Pfizer Investigational Site
Esbjerg, 6700, Denmark
Pfizer Investigational Site
Fredericia, 7000, Denmark
Pfizer Investigational Site
Frederiksberg, 2000, Denmark
Pfizer Investigational Site
Frederikssund, 3600, Denmark
Pfizer Investigational Site
Grenå, 8500, Denmark
Pfizer Investigational Site
Hjørring, 9800, Denmark
Pfizer Investigational Site
Holbak, 4300, Denmark
Pfizer Investigational Site
Holstebro, 7500, Denmark
Pfizer Investigational Site
Hvidovre, 2650, Denmark
Pfizer Investigational Site
Kabenhavn S, 2300, Denmark
Pfizer Investigational Site
Kalundborg, 4400, Denmark
Pfizer Investigational Site
København NV, 2400, Denmark
Pfizer Investigational Site
Kobenhavn K, 1256, Denmark
Pfizer Investigational Site
København NV, 2400, Denmark
Pfizer Investigational Site
Køge, 4600, Denmark
Pfizer Investigational Site
Middelfart, 5500, Denmark
Pfizer Investigational Site
Nykøbing Falster, 4800, Denmark
Pfizer Investigational Site
Næstved, 4700, Denmark
Pfizer Investigational Site
Odder, 8300, Denmark
Pfizer Investigational Site
Randers, 8900, Denmark
Pfizer Investigational Site
Roskilde, 4000, Denmark
Pfizer Investigational Site
Silkeborg, 8600, Denmark
Pfizer Investigational Site
Skive, 7800, Denmark
Pfizer Investigational Site
Slagelse, 4200, Denmark
Pfizer Investigational Site
Svendborg, 5700, Denmark
Pfizer Investigational Site
Ekenäs, 10600, Finland
Pfizer Investigational Site
Heinola, 18100, Finland
Pfizer Investigational Site
Helsinki, 00029, Finland
Pfizer Investigational Site
Helsinki, 00100, Finland
Pfizer Investigational Site
Joensuu, 80210, Finland
Pfizer Investigational Site
Jyväskylä, 40100, Finland
Pfizer Investigational Site
Kerava, 04200, Finland
Pfizer Investigational Site
Kuopio, 70210, Finland
Pfizer Investigational Site
Lahti, 15110, Finland
Pfizer Investigational Site
Lappeenranta, 53130, Finland
Pfizer Investigational Site
Lohja, 08200, Finland
Pfizer Investigational Site
Mikkeli, 50100, Finland
Pfizer Investigational Site
Rauma, 26100, Finland
Pfizer Investigational Site
Salo, 24130, Finland
Pfizer Investigational Site
Siaraalamaki, 45750, Finland
Pfizer Investigational Site
Tampere, 33520, Finland
Pfizer Investigational Site
Vantaa, 01400, Finland
Pfizer Investigational Site
Reykjavik, 101, Iceland
Pfizer Investigational Site
Reykjavik, 108, Iceland
Pfizer Investigational Site
's-Hertogenbosch, 5211 NL, Netherlands
Pfizer Investigational Site
Alkmaar, 1815 JD, Netherlands
Pfizer Investigational Site
Amsterdam, 1061 AE, Netherlands
Pfizer Investigational Site
Assen, 9401 RK, Netherlands
Pfizer Investigational Site
Breda, 4818 CK, Netherlands
Pfizer Investigational Site
Capelle aan den IJssel, 2906 ZC, Netherlands
Pfizer Investigational Site
Delft, 2625 AD, Netherlands
Pfizer Investigational Site
Deventer, 7415 CM, Netherlands
Pfizer Investigational Site
Ede, 6716 RP, Netherlands
Pfizer Investigational Site
Eindhoven, 5623 EJ, Netherlands
Pfizer Investigational Site
Enschede, 7511 JX, Netherlands
Pfizer Investigational Site
Goes, 4462 RA, Netherlands
Pfizer Investigational Site
Groningen, 9721 SW, Netherlands
Pfizer Investigational Site
Hoorn, 1624 GM, Netherlands
Pfizer Investigational Site
Nijmegen, 6532 SZ, Netherlands
Pfizer Investigational Site
Oss, NL-5342 BT, Netherlands
Pfizer Investigational Site
Rotterdam, 3045 PM, Netherlands
Pfizer Investigational Site
Tilburg, 5022 GC, Netherlands
Pfizer Investigational Site
Tilurg, 5022 GC, Netherlands
Pfizer Investigational Site
Utrecht, NL-3508-TG, Netherlands
Pfizer Investigational Site
Weert, 6001 BE, Netherlands
Pfizer Investigational Site
Zwijndrecht, 3331 LZ, Netherlands
Pfizer Investigational Site
Zwolle, 8011 JW, Netherlands
Pfizer Investigational Site
Ålesund, 6002, Norway
Pfizer Investigational Site
Ålesund, 6026, Norway
Pfizer Investigational Site
Bergen, 5008, Norway
Pfizer Investigational Site
Bergen, 5009, Norway
Pfizer Investigational Site
Bergen, 5012, Norway
Pfizer Investigational Site
Bergen, 5015, Norway
Pfizer Investigational Site
Bergen, 5021, Norway
Pfizer Investigational Site
Bodø, 8092, Norway
Pfizer Investigational Site
Flekkefjord, 4400, Norway
Pfizer Investigational Site
Førde, 6807, Norway
Pfizer Investigational Site
Hammerfest, 9613, Norway
Pfizer Investigational Site
Haugesund, 5500, Norway
Pfizer Investigational Site
Hobøl, 1827, Norway
Pfizer Investigational Site
Jessheim, 2050, Norway
Pfizer Investigational Site
Karasjok, 9735, Norway
Pfizer Investigational Site
Kongsberg, 3600, Norway
Pfizer Investigational Site
Kongsvinger, 2226, Norway
Pfizer Investigational Site
Kragerø, 3770, Norway
Pfizer Investigational Site
Kristiansand, 4612, Norway
Pfizer Investigational Site
Kristiansund N, 6508, Norway
Pfizer Investigational Site
Larvik, 3257, Norway
Pfizer Investigational Site
Levanger, 7600, Norway
Pfizer Investigational Site
Lillestom, 2000, Norway
Pfizer Investigational Site
Lorenskog, 1478, Norway
Pfizer Investigational Site
Mo i Rana, 8607, Norway
Pfizer Investigational Site
Molde, 6407, Norway
Pfizer Investigational Site
Molde, 6415, Norway
Pfizer Investigational Site
Mosjøen, 8656, Norway
Pfizer Investigational Site
Moss, 1502, Norway
Pfizer Investigational Site
Mysen, 1850, Norway
Pfizer Investigational Site
Nesttun, 5221, Norway
Pfizer Investigational Site
Notodden, 3675, Norway
Pfizer Investigational Site
Odda, 5750, Norway
Pfizer Investigational Site
Oslo, 0027, Norway
Pfizer Investigational Site
Oslo, 0160, Norway
Pfizer Investigational Site
Oslo, 0264, Norway
Pfizer Investigational Site
Oslo, 0303, Norway
Pfizer Investigational Site
Oslo, 0407, Norway
Pfizer Investigational Site
Oslo, 0456, Norway
Pfizer Investigational Site
Oslo, 0514, Norway
Pfizer Investigational Site
Oslo, 0913, Norway
Pfizer Investigational Site
Paradis, 5231, Norway
Pfizer Investigational Site
Porsgrunn, 3922, Norway
Pfizer Investigational Site
Rud, 1309, Norway
Pfizer Investigational Site
Sandvika, 1301, Norway
Pfizer Investigational Site
Skedsmokorset, N-2020, Norway
Pfizer Investigational Site
Ski, 1400, Norway
Pfizer Investigational Site
Stavanger, 4004, Norway
Pfizer Investigational Site
Stavanger, 4006, Norway
Pfizer Investigational Site
Stavanger, 4023, Norway
Pfizer Investigational Site
Stavanger, 4095, Norway
Pfizer Investigational Site
Stord, 5400, Norway
Pfizer Investigational Site
Tansberg, 3191, Norway
Pfizer Investigational Site
Trondheim, 7001, Norway
Pfizer Investigational Site
Trondheim, 7011, Norway
Pfizer Investigational Site
Tynset, 2500, Norway
Pfizer Investigational Site
Tønsberg, 3103, Norway
Pfizer Investigational Site
Volda, 6100, Norway
Pfizer Investigational Site
Alingsås, 441 83, Sweden
Pfizer Investigational Site
Ängelholm, 262 81, Sweden
Pfizer Investigational Site
Bålsta, 746 32, Sweden
Pfizer Investigational Site
Borås, 501 82, Sweden
Pfizer Investigational Site
Eksjö, 575 81, Sweden
Pfizer Investigational Site
Eskilstuna, 631 88, Sweden
Pfizer Investigational Site
Fagersta, 737 81, Sweden
Pfizer Investigational Site
Falköping, 521 85, Sweden
Pfizer Investigational Site
Falun, 791 82, Sweden
Pfizer Investigational Site
Finspång, 612 25, Sweden
Pfizer Investigational Site
Gateborg, 41345, Sweden
Pfizer Investigational Site
Gävle, 800 02, Sweden
Pfizer Investigational Site
Gävle, 801 87, Sweden
Pfizer Investigational Site
Gävle, 802 57, Sweden
Pfizer Investigational Site
Gävle, 802 84, Sweden
Pfizer Investigational Site
Gothenburg, 413 45, Sweden
Pfizer Investigational Site
Gothenburg, 417 17, Sweden
Pfizer Investigational Site
Grästorp, 46722, Sweden
Pfizer Investigational Site
Halmstad, 301 85, Sweden
Pfizer Investigational Site
Hässleholm, 281 25, Sweden
Pfizer Investigational Site
Hässleholm, 281 31, Sweden
Pfizer Investigational Site
Helsingborg, 252 20, Sweden
Pfizer Investigational Site
Helsingborg, 252 21, Sweden
Pfizer Investigational Site
Hudiksvall, 824 81, Sweden
Pfizer Investigational Site
Jönköping, 55185, Sweden
Pfizer Investigational Site
Kalmar, 391 85, Sweden
Pfizer Investigational Site
Karlshamn, 374 80, Sweden
Pfizer Investigational Site
Karlskoga, S-691 81, Sweden
Pfizer Investigational Site
Karlskrona, 371 85, Sweden
Pfizer Investigational Site
Karlstad, 651 85, Sweden
Pfizer Investigational Site
Katarineholm, 641 22, Sweden
Pfizer Investigational Site
Köping, 731 80, Sweden
Pfizer Investigational Site
Kristinehamn, 681 80, Sweden
Pfizer Investigational Site
Lidköping, 531 85, Sweden
Pfizer Investigational Site
Linka Ping, 581 85, Sweden
Pfizer Investigational Site
Ljungby, 341 82, Sweden
Pfizer Investigational Site
Ludvika, 771 81, Sweden
Pfizer Investigational Site
Luleå, 971 80, Sweden
Pfizer Investigational Site
Lycksele, 921 82, Sweden
Pfizer Investigational Site
Malmo, 205 02, Sweden
Pfizer Investigational Site
Malmo, 211 20, Sweden
Pfizer Investigational Site
Malmo, 211 38, Sweden
Pfizer Investigational Site
Malmo, 214 22, Sweden
Pfizer Investigational Site
Mariestad, 542 24, Sweden
Pfizer Investigational Site
Motala, 591 85, Sweden
Pfizer Investigational Site
Mölndal, 431 80, Sweden
Pfizer Investigational Site
Norrköping, 601 82, Sweden
Pfizer Investigational Site
Sala, 733 25, Sweden
Pfizer Investigational Site
Sandviken, 811 89, Sweden
Pfizer Investigational Site
Skellefteå, 931 86, Sweden
Pfizer Investigational Site
Skene, 511 81, Sweden
Pfizer Investigational Site
Skövde, 541 85, Sweden
Pfizer Investigational Site
Södertälje, 151 72, Sweden
Pfizer Investigational Site
Stockholm, 111 35, Sweden
Pfizer Investigational Site
Stockholm, 113 22, Sweden
Pfizer Investigational Site
Stockholm, 113 82, Sweden
Pfizer Investigational Site
Stockholm, 114 86, Sweden
Pfizer Investigational Site
Stockholm, 116 25, Sweden
Pfizer Investigational Site
Stockholm, 118 83, Sweden
Pfizer Investigational Site
Strömstad, 452 83, Sweden
Pfizer Investigational Site
Uddevalla, 451 80, Sweden
Pfizer Investigational Site
Umeå, 901 85, Sweden
Pfizer Investigational Site
Varberg, 432 81, Sweden
Pfizer Investigational Site
Vänersborg, 46235, Sweden
Pfizer Investigational Site
Västervik, 593 81, Sweden
Pfizer Investigational Site
Related Publications (9)
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437.
PMID: 16287954RESULTTunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
PMID: 38018702DERIVEDPorts WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
PMID: 28573499DERIVEDStam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648.
PMID: 28214794DERIVEDDeedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.
PMID: 27513651DERIVEDStoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16.
PMID: 25595417DERIVEDDorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14.
PMID: 23674398DERIVEDSemb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524.
PMID: 22576673DERIVEDHyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3.
PMID: 20130232DERIVED
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 8, 2005
First Posted
September 12, 2005
Study Start
February 1, 1999
Study Completion
March 1, 2005
Last Updated
April 22, 2015
Record last verified: 2015-04